A phase I/II study of RAD001 [everolimus] with docetaxel in the treatment of metastatic, androgen independent prostate cancer.
Phase of Trial: Phase I/II
Latest Information Update: 26 May 2016
At a glance
- Drugs Everolimus (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 19 Feb 2013 Planned end date changed from 1 Mar 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 05 Sep 2012 Planned End Date changed from 1 Dec 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.